Skip to main content
Log In
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
Basket
Search
More
Search for this keyword
Advanced search
Latest content
Browse by collection
Archive
Authors
About
Search for this keyword
Advanced search
Close
More
Main menu
Latest content
Browse by collection
Archive
Authors
About
Log in
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
BMJ Journals
You are here
Home
Archive
Volume 9, Issue 2
Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany
Email alerts
Article metrics
Article menu
Article
Text
Article
info
Citation
Tools
Share
Rapid Responses
Article
metrics
Alerts
This article has a correction. Please see:
Correction: Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany - October 01, 2021
PDF
XML
Oncolytic and local immunotherapy
Original research
Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany
Online download statistics by month:
Online download statistics by month: February 2021 to March 2024
Abstract
Full
Pdf
Feb 2021
306
306
109
Mar 2021
208
208
71
Apr 2021
119
119
43
May 2021
155
155
75
Jun 2021
125
125
25
Jul 2021
129
129
24
Aug 2021
115
115
68
Sep 2021
162
162
38
Oct 2021
125
127
44
Nov 2021
166
167
54
Dec 2021
121
121
16
Jan 2022
114
118
29
Feb 2022
92
95
24
Mar 2022
147
149
37
Apr 2022
136
141
32
May 2022
185
192
41
Jun 2022
133
139
32
Jul 2022
120
124
24
Aug 2022
115
118
18
Sep 2022
117
117
29
Oct 2022
96
97
32
Nov 2022
97
98
22
Dec 2022
72
72
32
Jan 2023
101
103
28
Feb 2023
118
119
25
Mar 2023
115
117
27
Apr 2023
84
90
46
May 2023
108
108
24
Jun 2023
139
139
22
Jul 2023
125
125
20
Aug 2023
100
105
15
Sep 2023
101
108
22
Oct 2023
121
121
18
Nov 2023
163
163
30
Dec 2023
191
192
21
Jan 2024
39
40
55
Feb 2024
84
84
9
Mar 2024
131
133
63
Total
4875
4941
1344
Read the full text or download the PDF:
Subscribe
Log in
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?